Komorki Raji, P3HR-1 i Namalwa jako model badania reaktywacji zakazenia wirusem Epsteina-Barr [EBV]

• Autorzy: Rek O. , Czescik A. , Trzcinska A. , Siennicka J.

Warianty tytułu

EN

Raji, P3HR-1 and Namalwa cells as a model for the study of Epstein-Barr virus [EBV] reactivation

• Języki publikacji: PL

Abstrakty

PL

Przedstawiono charakterystykę linii komórkowych wyprowadzonych z chło- niaka Burkitt'a (Raji, P3HR-1 i Namalwa) dotyczącą warunków wzrostu, obecności genomu wirusa EBV, oraz ekspresji receptorów Toll-like (TLR 2, TLR3, TLR 4).

EN

The aim of the study was to characterize Raji, P3HR-1 and Namalwa cell lines in the aspect of their usefulness for the research on virus Epstein-Barr (EBV) reactivation, with the participation of Toll-like receptors (TLR). During a 12-day experiment, optimal conditions of cultivation (RPMI with 10% FCS at 37°C in 5% CO2) were determined. In these conditions cells showed logarithmic growth. The presence of the DNA EBV was confirmed by the PCR method, showing that 12-day long maintenance of cells does not cause the loss of the virus. The presence of genes encoding TLR2, TLR3 and TLR4 was also confirmed by PCR. The TLRs expression at the mRNA level in cells subjected to 24h stimulation with TLR2, TLR3 and TLR4 agonist (Pam3CSK4, Poly(I:C) and LPS, respectively) was determined by the RT PCR method. The presence of TLR4 mRNA was confirmed in the case of Namalwa cells stimulated by Pam3CSK and LPS, and P3HR cells stimulated by Pam3CSK4. In the case of Raji cells the expression of none of the receptors was confirmed at the mRNA level in cells with and without stimulation.

Słowa kluczowe

PL

linie komorkowe; chloniaki; latencja wirusowa; wirusy; zakazenia wirusowe; wirus Epsteina-Barr; komorki P3HR-1; genom wirusa

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2010
• Tom: 62
• Numer: 3
• Opis fizyczny: s.263-269,rys.,wykr.,bibliogr.

Twórcy

autor

Rek O.

• Zaklad Wirusologii, Narodowy Instytut Zdrowia Publicznego - Panstwowy Zaklad Higieny, ul.Chocimska 24, 00-791 Warszawa

autor

Czescik A.

autor

Trzcinska A.

autor

Siennicka J.

Bibliografia

• 1. Adamson AL, Darr D, Holley-Guthrie E, Johnson RA et al. Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases. J Virol 2000; 74: 1224-33.
• 2. Decausin G, Leclerc V, Ooke T. The lytic cycle of Epstein-Barr virus in non-producer Raji line can be rescued by the expression of e 135 kDa protein encoded by BALF2 ORF deleted cells. J Virol 1995; 69: 7309-14.
• 3. Epstein MA & Barr YM. Characteristics and mode of growth of tissue culture strain (EB1) of human lymphoblasts from Birkitt's lymphoma. J Natl Cancer Inst 1965; 34: 231-40.
• 4. Henault M, Lee LN, Evans GF, Zuckerman SH. The human Burkitt lymphoma cell line Namalwa represents a homogenous cell system characterized by high levels of Toll-like receptor 9 and activation by CpG oligonucleotides. J Immunol Methods 2005; 300: 93-9.
• 5. Hummel M, Abecassis MM. A model for reactivation of CMV from latency. Journal of Clinical Virology 2002; 25: S123-S136.
• 6. Jarnsens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clinical Microbiology Reviews. 2003; 637-46.
• 7. Johannsen EC, Schooley RT, Kaye KK. Epstein-Barr Virus (Infectious Mononucleosis). W: Principles and practice of infectious diseases. Mandeli GL, Benett GL, Dolin R. 6th edn. Elsevier, 2005; 1801-15.
• 8. Kalla M, Schmeinck A, Bergbauer M, Pich D et al. AP-1 homolog BZLF1 of Epstein-Barr virus has two essential functions dependent on the epigenetic state of the viral genome. Proc Natl Acad Sci 2010; 107: 850-5.
• 9. Kieff E, Levine J. Homology between Burkitt herpes viral DNA and DNA in continuous lympho- blastoid cells from patients with infectious mononucleosis. Proc Natl Acad Sci USA 1974; 71: 355-8.
• 10. Lu JH, Tang YL, Yu HB, Zhou JH et al. Epstein-Barr virus facilitates the malignant potential of immortalized epithelial cells: from latent genome to viral production and maintenance. Lab Invest 2010; 90: 196-209.
• 11. Matusali G, Arena G, De Leo A, Di Renzo L et al. Inhibition of p38 MAP kinase pathway induces apoptosis and prevents Epstein Barr virus reactivation in Raji cells exposed to lytic cycle inducing compounds. Molecular Cancer 2009; 8:18.
• 12. Muzio M, Bosisio D, Polentarutti N, D 'Amico G, Stoppacciaro A, Mancinelli R, van't Veer C, Penton-Rol G, Ruco P, Allavena P, Montováni A. Differential expression and regulation of Toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol 2000; 164: 5998-6004.
• 13. Pozo F, Tenorio A. Detection and typing of lymphotropic herpesviruses by multiplex polymerase chain reaction. J Virol Methods 1999; 79: 9-19.
• 14. Pulvertaft RJ. Phytohaemagglutinin in relation to Burkitt's tumor (African lymphoma). Lancet 1964; 14: 552-4.
• 15. Rabson M et al. Non-immortalizing P3J-HR-1 Epstein-Barr virus: a deletion mutant of its transforming parent, Jijoye. J Virol 1982; 44: 834-44.
• 16. Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol 2008; 325: 297-313.
• 17. Tokarz-Deptuła B, Niedźwiedzka P, Deptuła W. Receptory Toll-podobne -nowe znaczniki w immunologii. Alergia Astma Immunologia 2006; 11: 23-8.
• 18.Watanabe A, Maruo S, Ito T, Ito M et al. Epstein-Barr virus-encoded Bcl-2 homologue functions as a survival factor in Wp-restricted Burkitt lymphoma cell line P3HR-1. J Virol. 2010; 84: 2893- 901.
• 19. Xie P, Kraus ZJ, Stunz LL, Bishop GA. Roles of TRAF molecules in В lymphocyte function. Cytokine Growth Factor Rev. 2008; 19: 199-207.
• 20. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. The Journal of Immunology 2002; 168: 554-61.
• 21. Żeromski J, Mozer-Lisewska I, Kaczmarek M. Ekspresja receptorów Toll-podobnych na krwinkach białych krwi obwodowej u dzieci z przewlekłym wirusowym zapaleniem wątroby typu C. Przegląd epidemiologiczny 2006; 60: 657-63.